Start Date
May 31, 2015
Primary Completion Date
October 31, 2020
Study Completion Date
October 31, 2022
ceritinib
Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
Duke University Medical Center, Durham
Collaborators (1)
Novartis
INDUSTRY
Anne Beaven, MD
OTHER